Towards the Application of a Label-Free Approach for Anti-CD47/PD-L1 Bispecific Antibody Discovery
The engineering of bispecific antibodies that exhibit optimal affinity and functional activity presents a significant scientific challenge. To tackle this, investigators employ an assortment of protein assay techniques, such as label-free interaction methodologies, which offer rapidity and convenien...
Main Authors: | Artem S. Grevtsev, Alexandra D. Azarian, Alexey K. Misorin, Daria O. Chernyshova, Pavel A. Iakovlev, Mikhail S. Karbyshev |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-12-01
|
Series: | Biosensors |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6374/13/12/1022 |
Similar Items
-
Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy
by: Irene Tang, et al.
Published: (2023-05-01) -
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
by: Tianye Li, et al.
Published: (2024-03-01) -
IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy
by: Chunmei Yang, et al.
Published: (2024-11-01) -
Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy
by: Yun Yang, et al.
Published: (2023-12-01) -
Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors
by: Eric Hatterer, et al.
Published: (2020-01-01)